Califf: More Expedited Approvals Mean US Clearance Only The Beginning Of Learning About Medical Products
Executive Summary
The US FDA commissioner said increased use of expedited approval pathways will help spur clinical research system reform.
You may also be interested in...
US FDA Commissioner Califf Expects To Leave Post Following 2024 Elections
Outlining what changes he wants to see at the agency before he leaves, Califf also worries congressional inaction on the user fee reauthorization could affect hiring efforts.
Califf Appears To Set 2025 As End Of His Term As US FDA Commissioner
Outlining what changes he wants to see at the agency before he leaves, Califf also worries congressional inaction on the user fee reauthorization could affect hiring efforts.
CBER Will Devote More Time To Non-COVID-19 Work Beginning In Six Months
Center for Biologics and Evaluation and Research is to resume normal operations at the beginning of 2023 and will stop prioritizing resources for COVID-19 regulatory work over non-COVID-19 matters.